

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information only and is not intended to and does not constitute, or form part of, an invitation or offer to acquire, purchase or subscribe for any securities of the Company.*



**Shanghai HeartCare Medical Technology  
Corporation Limited**

**上海心瑋醫療科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6609)**

**EXTENSION OF THE VALIDITY PERIOD OF THE RESOLUTIONS  
CONCERNING THE A SHARE ISSUE AND THE AUTHORIZATION  
CONCERNING THE A SHARE ISSUE;  
PROPOSED CHANGE OF REGISTERED ADDRESS  
AND  
PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION**

**Proposed Extension of the Validity Period of the Resolutions Concerning the A Share Issue and the Authorization Concerning the A Share Issue**

References are made to the announcements of the Company dated November 8, 2023, October 16, 2023, November 9, 2022, and October 10, 2022 and the circulars of the Company dated October 20, 2023 and October 24, 2022 in relation to, among others, the Resolutions concerning the A Share Issue and the Authorization concerning the A Share Issue.

On November 9, 2022, the 2022 First Extraordinary General Meeting, the 2022 First Class Meeting of H Shareholders and the 2022 First Class Meeting of Domestic Shareholders and Unlisted Foreign Shareholders were held and the Resolutions concerning the A Share Issue and the Authorization concerning the A Share Issue were passed. The validity period of the resolutions were 12 months from November 9, 2022. On November 8, 2023, in order to extend the validity period of the aforementioned resolutions, the 2023 Extraordinary General Meeting, the 2023 Class Meeting of H Shareholders and the 2023 Class Meeting of Domestic Shareholders and Unlisted Foreign Shareholders were held, and the extension of the validity period of the Resolutions concerning the A Share Issue and the Authorization

concerning the A Share Issue were approved. The validity period of the Resolutions concerning the A Share Issue and the Authorization concerning the A Share Issue were extended to the 12 months ending after November 8, 2023 (i.e. November 7, 2024).

As of the date of this announcement, given that the A Share Issue is still in progress and the validity period of the Resolutions concerning the A Share Issue and the Authorization concerning the A Share Issue will expire on November 7, 2024, it is reasonable to propose to extend the validity period of the Resolutions concerning the A Share Issue and the Authorization concerning the A Share Issue for 12 months in consideration of the current progress of the A Share Issue. The Board proposes to extend the validity period of the Resolutions concerning the A Share Issue and the Authorization concerning the A Share Issue for 12 months from the date on which they are to be considered and approved at an upcoming extraordinary general meeting, H Shares class meeting and Unlisted Shares class meeting, for the purpose of ensuring the on-going proceeding of the A Share Issue.

Save for the abovementioned proposed extension of the validity period for the Resolutions concerning the A Share Issue and the Authorization concerning the A Share Issue as disclosed in this announcement, all other terms of the A Share Issue as set out in the circulars of the Company dated October 20, 2023 and October 24, 2022 will remain unchanged.

**As the A Share Issue is subject to approval of CSRC, relevant stock exchange in the PRC and other relevant regulatory authorities may or may not proceed, Shareholders and investors are reminded to exercise caution when dealing in the H Shares of the Company. The Company will make further announcements on any material updates and developments in relation to the A Share Issue in accordance with the Listing Rules and other applicable laws and regulations.**

### **Proposed Change of Registered Address**

The Board proposes to change the registered address of the Company from “Floor 1 and 3, Building 38, No. 356, Zhengbo Road, Lingang New District, Pilot Free Trade Zone, Shanghai, PRC” to “Building 38, No. 356, Zhengbo Road, Lingang New District, Pilot Free Trade Zone, Shanghai, PRC” so as to meet the actual needs of business development.

### **Proposed Amendments to the Articles of Association**

The Board proposes to make certain amendments to the Articles of Association in order to reflect the proposed change of registered address of the Company, and to bring the Articles of Association to be in line with the relevant requirements of the applicable laws including but not limited to the Company Law of the PRC, and taking the practical circumstances of the Company into consideration.

## Extraordinary General Meeting

The above resolutions relating to the extension of the validity period of the Resolutions concerning the A Share Issue and the Authorization concerning the A Share Issue and the proposed amendments of the Articles of Association will be submitted by way of special resolution(s) at the forthcoming extraordinary general meeting, the H Shares class meeting and the Unlisted Shares class meeting of the Company for consideration and approval (as might be applicable). The above resolution relating to the proposed change of registered address of the Company will be submitted by way of an ordinary resolution at the forthcoming extraordinary general meeting of the Company for consideration and approval (as might be applicable). A circular containing, among others, the details of the above resolutions, together with notices convening the extraordinary general meeting, H Shares class meeting and Unlisted Shares class meeting, are expected to be sent to the Shareholders in the manner as they elect to receive corporate communications in due course.

## DEFINITIONS

“2022 First Class Meeting of Domestic Shareholders and Unlisted Foreign Shareholders”	the class meeting of Domestic Shareholders and Unlisted Foreign Shareholders held on November 9, 2022, details of which are set out in the announcement of the Company dated November 9, 2022 and the circular of the Company dated October 24, 2022
“2022 First Class Meeting of H Shareholders”	the class meeting of H Shareholders held on November 9, 2022, details of which are set out in the announcement of the Company dated November 9, 2022 and the circular of the Company dated October 24, 2022
“2022 First Extraordinary General Meeting”	the extraordinary general meeting of the Company held on November 9, 2022, details of which are set out in the announcement of the Company dated November 9, 2022 and the circular of the Company dated October 24, 2022
“2023 Class Meeting of Domestic Shareholders and Unlisted Foreign Shareholders”	the class meeting of Domestic Shareholders and Unlisted Foreign Shareholders held on November 8, 2023, details of which are set out in the announcement of the Company dated November 8, 2023 and the circular of the Company dated October 20, 2023
“2023 Class Meeting of H Shareholders”	the class meeting of H Shareholders held on November 8, 2023, details of which are set out in the announcement of the Company dated November 8, 2023 and the circular of the Company dated October 20, 2023

“2023 Extraordinary General Meeting”	the extraordinary general meeting of the Company held on November 8, 2023, details of which are set out in the announcement of the Company dated November 8, 2023 and the circular of the Company dated October 20, 2023
“A Share(s)”	the ordinary share(s) with a nominal value of RMB1.00 each in the share capital of the Company proposed to be allotted, issued and listed on the Sci-Tech Board
“A Share Issue” or “Issue of A Shares” or “Issue”	the proposed initial public issue of not more than 13,000,000 A Shares, which will be listed on the Sci-Tech Board, details of which are set out in the circulars of the Company dated October 20, 2023 and October 24, 2022
“Articles of Association”	the articles of association of the Company currently in force
“Authorization concerning the A Share Issue”	The authorization concerning the A Share Issue granted to the Directors which was considered and approved at the 2022 First Extraordinary General Meeting, the 2022 First Class Meeting of H Shareholders and the 2022 First Class Meeting of Domestic Shareholders and Unlisted Foreign Shareholders of the Company held on November 9, 2022, and was considered and approved for an extension for a validity period of 12 months at the 2023 Extraordinary General Meeting, the 2023 Class Meeting of H Shareholders and the 2023 Class Meeting of Domestic Shareholders and Unlisted Foreign Shareholders of the Company held on November 8, 2023
“Board of Directors” or “Board”	the board of directors of the Company
“China” or the “PRC”	the People’s Republic of China, for the purpose of this announcement, excluding the regions of Hong Kong, Macao Special Administrative Region of the People’s Republic of China and Taiwan
“Company”	Shanghai HeartCare Medical Technology Corporation Limited (上海心瑋醫療科技股份有限公司), a joint stock limited liability company incorporated in the PRC, whose H Shares are listed on the Hong Kong Stock Exchange (Stock Code: 6609)
“CSRC”	China Securities Regulatory Commission

“Director(s)”	the director(s) of the Company
“Domestic Share(s)”	ordinary share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, which are subscribed for and paid up in Renminbi
“H Share(s)”	overseas listed foreign share(s) in the ordinary share capital of the Company with a nominal value of RMB1.00 each, which are subscribed for and traded in Hong Kong Dollars and listed on the Stock Exchange
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended from time to time
“Resolutions concerning the A Share Issue”	the resolutions concerning the A Share Issue which were considered and approved at the 2022 First Extraordinary General Meeting, the 2022 First Class Meeting of H Shareholders and the 2022 First Class Meeting of Domestic Shareholders and Unlisted Foreign Shareholders of the Company held on November 9, 2022, and the resolutions concerning the extension of the validity period of the resolutions concerning the A Share Issue which were considered and approved at the 2023 Extraordinary General Meeting, the 2023 Class Meeting of H Shareholders and the 2023 Class Meeting of Domestic Shareholders and Unlisted Foreign Shareholders of the Company held on November 8, 2023
“RMB” or “Renminbi”	Renminbi, the lawful currency of the PRC
“Share(s)”	ordinary share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, comprising Domestic Share(s), Unlisted Foreign Share(s) and H Share(s)
“Shareholder(s)”	holder(s) of the Shares
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Unlisted Foreign Share(s)”	ordinary share(s) in the share capital of the Company with a nominal value of RMB1.00 each, which are subscribed for and paid for in currency other than RMB by foreign investors and are not listed on any stock exchange

“Unlisted Share(s)”

Shares that are not listed on the Hong Kong Stock Exchange, being the total of Domestic Shares and Unlisted Foreign Shares

By Order of the Board  
**Shanghai HeartCare Medical Technology Corporation Limited**  
**WANG Guohui**  
*Chairman of the Board*

Shanghai, October 17, 2024

*As at the date of this announcement, the executive Directors are Mr. Wang Guohui, Ms. Zhang Kun and Mr. Wei Jiawei; the non-executive Directors are Mr. Ding Kui, Mr. Chen Shaoxiong and Mr. Chen Gang; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.*